Legally Speaking: Case Study: "Uterine atony"
December 1st 2002This is the second in a bimonthly series aimed at educating physicians on the pertinent aspects of litigation. Each case study will provide analysis of an actual ob/gyn lawsuit defended by the New York firm of Aaronson, Rappaport, Feinstein & Deutsch, LLP.
A role for expectant management in severe preeclampsia?
December 1st 2002Although controversial, delivery is usually recommended for all women with severe preeclampsia--regardless of gestational age. But premature delivery can pose a major threat to the periviable fetus. When is it appropriate to expectantly manage severe preeclampsia?
Emergency cerclage: What do the data really show?
October 1st 2002While cervical incompetence is an important contributor to many preterm births before 28 weeks, cerclage is not always the appropriate remedy. Candidates should be selected with care and the procedure contemplated only after consideration of benefits and risks to both mother and fetus and in-depth patient counseling.
Cover Story: Is that Pap specimen adequate?
October 1st 2002Even before Bethesda 2001 terminology recommended substantial changes in how labs should report Pap results--including specimen adequacy--many clinicians were confused about which patients to follow-up with repeat Pap tests. This article explains and clarifies the latest Pap test adequacy guidelines.
Obstetrics and diversity in the US: Se habla espanol?
September 1st 2002By helping Hispanic patients interact effectively with the health-care system, ob/gyns can increase the amount of prenatal care these women receive and decrease their high rates of preterm delivery and pregnancy-related maternal mortality.
Cover Story: Repeat antenatal corticosteroids: A time for caution
August 1st 2002While a single course of antenatal corticosteroids improves neonatal outcomes among infants born prematurely, the efficacy and safety of repetitive courses of ACS (including rescue dosing) is less clear. In the absence of adequate data to support a policy of repetitive dosing of ACS, such therapy should only be used as part of well-designed clinical trials.